Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline Testing in Prostate Cancer: When and Who to Test.

Oncology (Williston Park, N.Y.) - 20 Oct 2021

Sokolova Alexandra, Cheng Heather

Abstract excerpt

The results of multiple studies have shown that a substantial proportion of men with advanced prostate cancer carry germline DNA repair mutations. Germline testing in prostate cancer may inform treatment decisions and consideration for clinical trials. There are 2 FDA approved PARP inhibitors (PARPi), olaparib (Lynparza) and rucaparib (Rubraca), for the treatment of advanced prostate cancer with DNA repair...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair
Share to Genetic Counseling
Share to Genetic Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germ-Line Mutation

Share to Neoplasm Grading

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Practice Guidelines as Topic

Share to Prostatic Neoplasms

Source

Identifiers

PMID: 34669358
DOI: 10.46883/ONC.2021.3510.0645

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline Testing in Prostate Cancer: When and Who to Test.PMID 34669358Read ↗

Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease ManagementSemantic proximity Read ↗

Germline and somatic mutations in prostate cancer: Implications for treatment.Semantic proximity Read ↗

Germline mutations and prostate cancer: is it time to change treatment algorithms?Semantic proximity Read ↗

Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTCSemantic proximity Read ↗

Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)Semantic proximity Read ↗

Therapeutic targeting of the DNA damage response in prostate cancerSemantic proximity Read ↗

Genetic testing in prostate cancer management: Considerations informing primary care.Semantic proximity Read ↗

Genetic testing for the clinician in prostate cancer.Semantic proximity Read ↗

Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testingSemantic proximity Read ↗

Genetics and Screening in Prostate Cancer.Semantic proximity Read ↗

DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review.Semantic proximity Read ↗

Germline testing for prostate cancer: current state and opportunities for enhanced accessSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.